Salvador Rico, M.D., Ph.D.
Chief Medical Officer
Salvador Rico, M.D., Ph.D., is chief medical officer at Encoded Therapeutics and brings over 15 years of clinical research experience in the biopharmaceutical industry to the company.
Prior to joining Encoded, Dr. Rico served as senior vice president of clinical development at Audentes Therapeutics. He led the clinical development of AT132, an AAV-based gene therapy for X-Linked Myotubular Myopathy. He has participated in the design, conduct, and analysis of Phase I-IV clinical trials in multiple therapeutic areas, and successfully contributed to the FDA approval of multiple drugs, biological products, and medical devices including the INTERCEPT Blood System®, Intermezzo®, Hibor®, Champix®, Prolia,® Kerydin®, and others. Prior to joining Audentes, he led the clinical development teams at Cerus Corporation and Transcept Pharmaceuticals and was an investigator at the Centre for Drug Research, Hospital de la Santa Creu i Sant Pau in Barcelona, Spain.
Dr. Rico earned his Doctor of Medicine and Surgery degree from the National Autonomous University of Mexico and holds an M.S. and a Ph.D. (Summa Cum Laude) in pharmacology from the Universitat Autonoma de Barcelona.